Experimental CAR t therapy takes aim at tough lupus kidney cases

NCT ID NCT05938725

First seen Nov 01, 2025 · Last updated Apr 23, 2026 · Updated 20 times

Summary

This early-phase study tests a treatment called KYV-101, made from a patient's own immune cells, for people with lupus nephritis that hasn't improved with standard care. The goal is to see if it's safe and can help control kidney inflammation. Only 6 adults with active lupus kidney disease are taking part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Northwell Health

    Great Neck, New York, 11021, United States

  • Ohio State University Wexner Medical Center

    Columbus, Ohio, 43210, United States

  • Stanford University Medical Center

    Palo Alto, California, 94305, United States

  • University of Colorado

    Denver, Colorado, 80045, United States

  • University of Massachusetts Worcester

    Worcester, Massachusetts, 01655, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

Conditions

Explore the condition pages connected to this study.